Basis of Presentation and Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2015

Basis of Presentation and Summary of Significant Accounting Policies

Analysis of U.S. product sales allowances and accruals

	Three Months Ended September 30,				Nine Months Ended September 30,
	2015		2014		2015		2014
Gross U.S. product sales	$	145,131	$	41,396	$	407,238	$	113,550
Provision for U.S. product sales allowances and accruals:
Contractual adjustments		41,851		18,179		116,236		49,953
Governmental rebates		14,363		208		40,018		580
Total provision for U.S. product sales allowances and accruals		56,214		18,387		156,254		50,533
U.S. product sales, net	$	88,917	$	23,009	$	250,984	$	63,017

Schedule of customers representing 10% or more of revenues

	Three Months Ended September 30,				Nine Months Ended September 30,
	2015		2014		2015		2014
AmerisourceBergen Drug Corporation	28	%	40	%	25	%	39	%
McKesson Corporation	13	%	24	%	11	%	24	%
Cardinal Health, Inc.	7	%	18	%	5	%	18	%
Takeda Pharmaceuticals Company Limited	—	%	10	%	17	%	10	%

Schedule of customers representing greater than 10% of accounts receivable balances

	September 30, 2015		December 31, 2014
AmerisourceBergen Drug Corporation	41	%	45	%
McKesson Corporation	8	%	12	%